Evidence map›Paper›PMID 33369707›Full record

ArticleHepatology international2020

A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC.

Xia Sheng, Yuan Ji, Guo-Ping Ren, Chang-Li Lu, Jing-Ping Yun, Li-Hong Chen, Bin Meng, Li-Juan Qu, Guang-Jie Duan, Qing Sun and 31 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Xia Sheng *Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Rd, Shanghai, 200438, China.
Yuan Ji *Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Guo-Ping Ren *Department of Pathology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Chang-Li Lu *Department of Pathology, West China Hospital of Sichuan University, Chengdu, China.
Jing-Ping Yun *Department of Pathology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Li-Hong ChenDepartment of Pathology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, China.
Bin MengDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Li-Juan QuDepartment of Pathology, The 900Th Hospital of Joint Logistic Support Force, PLA, Fuzhou, China.
Guang-Jie DuanInstitute of Pathology and Southwest Cancer Center, Southwest Hospital, Chongqing, China.
Qing SunDepartment of Pathology, The First Affiliated Hospital of Shandong First Medical University, Jinan, China.
Xin-Qing YeDepartment of Pathology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
Shan-Shan LiDepartment of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Jing YangDepartment of Pathology, Guangzhou First People's Hospital, Guangzhou, China.
Bing LiaoDepartment of Pathology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Zhan-Bo WangDepartment of Pathology, The General Hospital of the People's Liberation Army, Beijing, China.
Jian-Hua ZhouDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, China.
Yu SunDepartment of Pathology, Peking University Cancer Hospital and Institute, Beijing, China.
Xue-Shan QiuDepartment of Pathology, The First Hospital of China Medical University, Shenyang, China.
Lei WangDepartment of Pathology, Fudan University Shanghai Cancer Center, 270 Dong An Rd, Shanghai, 200032, China.
Zeng-Shan LiDepartment of Pathology, Xijing Hospital, Fourth Military Medical University, Xian, China.
Jun ChenDepartment of Pathology, Nanjing Drum Tower Hospital, Nanjing, China.
Chun-Yan XiaDepartment of Pathology, Changzheng Hospital, Shanghai, China.
Song HeDepartment of Pathology, Affiliated Cancer Hospital of Nantong University, Nantong, China.
Chuan-Ying LiDepartment of Pathology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China.
En-Wei XuDepartment of Pathology, Shanxi Cancer Hospital, Taiyuan, China.
Jing-Shu GengDepartment of Pathology, Harbin Medical University Cancer Hospital, Harbin, China.
Chao PanDepartment of Pathology, Zhongshan Hospital, Xiamen University, Xiamen, China.
Dong KuangInstitute of Pathology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Rong QinDepartment of Pathology, The Second Hospital of Anhui Medical University, Hefei, China.
Hong-Wei GuanDepartment of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Zhan-Dong WangDepartment of Pathology, Xuzhou Cancer Hospital, Xuzhou, China.
Li-Xing LiGenome Wisdom Institute, 67 North Fourth Ring West Rd, Beijing, 100800, China.
Xi ZhangGenome Wisdom Institute, 67 North Fourth Ring West Rd, Beijing, 100800, China.
Han WangDepartment of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Rd, Shanghai, 200438, China.
Qian ZhaoDepartment of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Rd, Shanghai, 200438, China.
Bo WeiGenome Wisdom Institute, 67 North Fourth Ring West Rd, Beijing, 100800, China.
Wu-Jian ZhangGenome Wisdom Institute, 67 North Fourth Ring West Rd, Beijing, 100800, China.
Shao-Ping LingGenome Wisdom Institute, 67 North Fourth Ring West Rd, Beijing, 100800, China. frank.ling@genowis.com.
Xiang DuDepartment of Pathology, Fudan University Shanghai Cancer Center, 270 Dong An Rd, Shanghai, 200032, China. dx2008cn@163.com.
Wen-Ming CongDepartment of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, 225 Changhai Rd, Shanghai, 200438, China. wmcong@smmu.edu.cn.
Liver Cancer Pathology Group of China (LCPGC)

Funding

Creative Research Groups of National Natural Science Foundation of China 81521091National Key R&D Program of China 2016YFC0902400National Natural Science Foundation of China 81472278
6 · The paper itself

Abstract

BACKGROUND AND

aimsMicrovascular invasion (MVI) is a key pathological factor that severely affects the postoperative prognosis of patients with hepatocellular carcinoma (HCC). However, no MVI classification schemes based on standardized gross sampling protocols of HCC are available at present.

methods119 HCC specimens were sampled at multiple sites (3-, 7-, and 13 points) for the optimum MVI detection rate. 16,144 resected HCCs were graded as M0, M1 or M2 by adopting three-tiered MVI grading (MVI-TTG) scheme based on the seven-point sampling protocol (SPSP). Survival analyses were performed on 2573 patients to explore the advantages of MVI-TTG.

resultsThe MVI detection rate determined by SPSP was significantly higher than that determined by the 3-point sampling method (34.5% vs. 47.1%, p = 0.048), but was similar to that determined by the 13-point sampling method (47.1% vs. 51.3%, p = 0.517). Among 16,144 resected HCCs, the proportions of M0, M1 and M2 specimens according to SPSP were 53.4%, 26.2% and 20.4%, respectively. Postoperative survival analysis in 2573 HCC patients showed that the 3-year recurrence rates in M0, M1 and M2 MVI groups were 62.5%, 71.6% and 86.1%, respectively (p < 0.001), and the corresponding 3-year overall survival (OS) rates were 94.1%, 87.5% and 67.0%, respectively (p < 0.001). M1 grade was associated with early recurrence, while M2 grade was associated with both early and late recurrence. MVI-TTG had a larger area under the curve and net benefit rate than the two-tiered MVI grading scheme for predicting time to recurrence and OS.

conclusionsSPSP is a practical method to balance the efficacy of sampling numbers and MVI detection rates. MVI-TTG based on SPSP is a better prognostic predictor than the two-tiered MVI scheme. The combined use of SPSP and MVI-TTG is recommended for the routine pathological diagnosis of HCC.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsHumansMicrovesselsNeoplasm InvasivenessNeoplasm Recurrence, LocalRetrospective StudiesGradingHepatocellular carcinomaMicrovascular invasionPrognosisRecurrenceSampling

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.